SOPHiA GENETICS SA
SOPH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SOPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SOPH
SOPHiA GENETICS SA is a cloud-native software company in healthcare, focused on data-driven medicine and life sciences research through its multimodal data analysis platform.
Key risk: Continued net losses
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$692.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
SOPHiA GENETICS SA is a cloud-native software company in healthcare, focused on data-driven medicine and life sciences research through its multimodal data analysis platform.
- SOPHiA GENETICS is a cloud-native software company dedicated to data-driven medicine, standardizing and analyzing multimodal health data across decentralized locations [sec · filed 2026-03-03].
- The company reported net losses of $79.0 million for 2025 and $62.5 million for 2024, with an accumulated deficit of $519.3 million as of December 31, 2025 [sec · filed 2026-03-03].
- As of December 31, 2025, SOPHiA had cash & equivalents of $37.5M, shareholders' equity of $151.4M, and total debt of $65.4M [latest reported financials (authoritative, structured)].
- The company is expanding its biopharma business, which is still nascent, with offerings across Discovery, Development, and Deployment stages [sec · filed 2025-03-04].
- SOPHiA aims to drive customer adoption in the U.S. market, which it sees as its largest opportunity, through direct sales force investment [sec · filed 2026-03-03].
What works
- The company's cloud-native platform is designed to break down data silos and enable collective intelligence across healthcare institutions, which could drive adoption [sec · filed 2026-03-03].
- SOPHiA is expanding into biopharma solutions, including SOPHiA Trial Match and SOPHiA CDx, targeting a growing market for AI-driven drug development [sec · filed 2025-03-04].
- The company has a clear strategy to penetrate the U.S. market, which it identifies as its largest opportunity, by scaling its direct sales force [sec · filed 2026-03-03].
What to weigh
- SOPHiA has incurred net losses since inception, with a net loss of $79.0 million in 2025 and an accumulated deficit of $519.3 million as of December 31, 2025 [sec · filed 2026-03-03].
- The company expects to continue incurring losses for the foreseeable future as it invests heavily in R&D and sales expansion [sec · filed 2026-03-03].
- The biopharma business is still nascent, with initial focus on pilot programs, and may not generate significant revenue in the near term [sec · filed 2025-03-04].
- SOPHiA may not achieve its goal of becoming cash flow positive in the next few years, and failure to achieve profitability could depress market value [sec · filed 2026-03-03].
From the filings
Quoted directly from source documents.
SOPHiA reported a net loss of $79.0 million for 2025 and an accumulated deficit of $519.3 million.
“For the years ended December 31, 2025 and 2024, we reported net losses of $79.0 million and $62.5 million, respectively. As of December 31, 2025, we had an accumulated deficit of $519.3 million.”
SEC filings · March 3, 2026
SOPHiA is a cloud-native software company focused on data-driven medicine.
“We are a cloud-native software technology company in the healthcare space dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research.”
SEC filings · March 3, 2026
The company expects to continue incurring net losses.
“We have incurred net losses since our inception and expect to continue to incur losses for the foreseeable future.”
SEC filings · March 3, 2026
SOPHiA's biopharma business is nascent and focused on pilot programs.
“our biopharma business is still nascent with the initial focus on establishing pilot programs with large pharmaceutical and biotech companies”
SEC filings · March 4, 2025
Risks & what to watch (4)›
Key risks
- Continued net losses — SOPHiA has reported net losses since inception, with a $79.0 million loss in 2025 and an accumulated deficit of $519.3 million [sec · filed 2026-03-03].
- Cash flow uncertainty — The company may not achieve its goal of becoming cash flow positive in the next few years, which could impair market value [sec · filed 2026-03-03].
- Nascent biopharma business — The biopharma segment is still in pilot phase and may not generate significant revenue soon [sec · filed 2025-03-04].
- Dependence on U.S. market — SOPHiA's growth strategy relies heavily on penetrating the U.S. market, which carries execution risk [sec · filed 2026-03-03].
What to watch
- Progress toward cash flow positivity, as the company has stated a desire to achieve this in the next few years [sec · filed 2026-03-03].
- Adoption of biopharma solutions like SOPHiA Trial Match and SOPHiA CDx, which are still in early stages [sec · filed 2025-03-04].
- Revenue growth from the U.S. market, which SOPHiA sees as its largest opportunity [sec · filed 2026-03-03].
- Changes in net loss trends, given the company's history of significant losses and accumulated deficit [sec · filed 2026-03-03].
Sources: SEC filings · Generated August 24, 2026 · How we verify sources →
Run SOPHiA GENETICS SA through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SOPHiA GENETICS SA facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 2.46
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
1 buy · 125 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$100.9M
| Holder | Shares | Value |
|---|---|---|
| generation investment management llp | 6,789,560 | $33.6M |
| akre capital management llc | 3,719,140 | $18.4M |
| banque pictet & cie sa | 2,208,280 | $10.9M |
| royce & associates lp | 1,816,312 | $9.0M |
| principal financial group inc | 1,409,242 | $7.0M |
| kennedy capital management llc | 927,800 | $4.6M |
| essex investment management co llc | 692,809 | $3.4M |
| archon capital management llc | 441,413 | $2.2M |
| hodges capital management inc. | 435,836 | $2.2M |
| sei investments co | 357,888 | $1.8M |
Showing top 10 of 46 institutional holders of SOPHiA GENETICS SA. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 0.3%
- Days to cover
- 2.1
- Shares short
- 198,408
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SOPH short interestFrequently asked questions
What is the AI investment thesis for SOPHiA GENETICS SA?
SOPHiA GENETICS SA is a cloud-native software company in healthcare, focused on data-driven medicine and life sciences research through its multimodal data analysis platform.
Who is the CEO of SOPHiA GENETICS SA?
Mr. Ross Jordan Muken B.Sc. is the chief executive officer of SOPHiA GENETICS SA (SOPH).
Where is SOPHiA GENETICS SA headquartered?
SOPHiA GENETICS SA (SOPH) is headquartered in Rolle, Switzerland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.